(Q34975260)

5 August 2017

title

Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes (English)

1 reference

5 August 2017

0 references

3

Charles A Dinarello

1 reference

5 August 2017

Naoko Hara

1

1 reference

5 August 2017

Aimon K Alkanani

series ordinal

2

1 reference

5 August 2017

Danny Zipris

series ordinal

4

1 reference

5 August 2017

publication date

28 August 2013

1 reference

Journal of Molecular Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

92

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

93-102

1 reference

The stages of type 1A diabetes: 2005.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Epidemiology of type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Toll-like receptors and type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

The role of Toll-like receptor pathways in the mechanism of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Induction of type I diabetes by Kilham's rat virus in diabetes-resistant BB/Wor rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

IRF-7 is the master regulator of type-I interferon-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Immune responses to the major capsid protein during parvovirus infection of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Molecular biology of autonomous parvoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Prevention of virus-induced type 1 diabetes with antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

The role of the intestinal microbiota in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-013-1078-1

Innate immunity in type 1 diabetes

21 January 2018

1 reference

12 December 2020

Gamma interferon prevents diabetes in the BB rat.

1 reference

12 December 2020

Histone hyperacetylation is associated with amelioration of experimental colitis in mice

1 reference

12 December 2020

TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats

1 reference

12 December 2020

Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts.

1 reference

12 December 2020

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells

1 reference

12 December 2020

TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat

1 reference

12 December 2020

Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis

1 reference

12 December 2020

Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations

1 reference

12 December 2020

Inhibitors of histone deacetylases as anti-inflammatory drugs.

1 reference

12 December 2020

10.1007/S00109-013-1078-1

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1040928129

0 references

1 reference